Pfizer and Innovent partnered in a $10.5 billion deal to develop innovative cancer therapies and expand global oncology pipelines.
China's Innovent Biologics and U.S. pharmaceutical giant Pfizer have entered into a significant global licensing and collaboration agreement, potentially valued at up to $10.5 billion, to advance the research and development of 12 early-stage cancer medicines. This landmark deal, announced on May 28, 2026, underscores the increasing trend of global drugmakers seeking to leverage China's rapidly expanding biotech pipeline.
Under the terms of the agreement, Innovent will receive an upfront payment of 650 million. Additionally, the Chinese biopharmaceutical firm is eligible for up to 9.85 billion in development, regulatory, and commercial milestone payments, along with potential double-digit royalties on sales of any approved licensed products.
The collaboration encompasses a diverse portfolio of 12 oncology programs, including antibody-drug conjugates (ADCs) with novel payloads and multi-specific antibodies with differentiated immune-engaging features. Eight of these early-stage assets originated from Innovent, while four are Pfizer-proposed discovery programs. Innovent will be responsible for developing these programs through Phase 1 clinical trials, after which Pfizer will assume leadership for global development.
The deal is structured with a multi-tiered approach to licensing and commercialization. For four of the programs, Pfizer will receive an exclusive global license and bear all global development costs. For another four programs, Pfizer will obtain an exclusive license outside Greater China and be responsible for the majority of development costs. The remaining four programs will be co-developed globally, with shared development costs and co-commercialization in the United States and Europe, where profits will be shared. Innovent will retain rights in Greater China for these co-developed programs.
This strategic partnership is driven by both companies' complementary strengths. Innovent brings its scientific discovery capabilities and robust early clinical development expertise in oncology innovation, while Pfizer contributes its deep scientific expertise, global clinical development infrastructure, regulatory leadership, and commercial scale. The objective is to accelerate the development of innovative therapies and bring novel cancer medicines to patients worldwide more efficiently.
Economically, this deal highlights the significant investment flowing into China's biotech sector, with the value of such licensing agreements in the Greater China region experiencing a nearly tenfold increase since 2021, reaching an unprecedented $137.7 billion last year. For Innovent, the agreement provides substantial funding for its research and development efforts and expands its global reach through co-commercialization in key markets. For Pfizer, it strengthens its oncology pipeline and provides access to promising early-stage assets developed by Innovent, aligning with Pfizer's strategy to aggressively build out its oncology portfolio through partnerships. The transaction is anticipated to close in the third quarter of 2026, pending regulatory approvals.
